| Title |
Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study
|
|---|---|
| Published in |
Drug Safety, March 2016
|
| DOI | 10.1007/s40264-016-0412-2 |
| Pubmed ID | |
| Authors |
Ishak A. Mansi, Jenny English, Song Zhang, Eric M. Mortensen, Ethan A. Halm |
| Abstract |
Data suggest that the beneficial cardiovascular effects of statins are maximized after the first year of statin use; yet, the timeline of statin-associated adverse events is not well delineated. To examine the associations of short-term statin use (≤1 year) with short- and long-term adverse events and beneficial cardiovascular outcomes in a 'healthy' cohort. A cohort study of a healthy Tricare population (fiscal year [FY] 2002 through FY 2011) who have no cardiovascular disease, major comorbidities requiring medications, or functional limitations. Statin users used statins for 90-365 days during FY 2005 as their only prescription medication. Nonusers had medical encounters but did not receive prescription medications during FY 2005, and did not receive any statins throughout the study period from FY 2002 to FY 2011. Outcomes were the occurrence of major acute cardiovascular events, diabetes mellitus and its complications, kidney diseases, musculoskeletal diseases, obesity, cataracts, malignancy, and death. We matched 1525 statin users to 1525 nonusers. During the follow-up period (FY 2006 to FY 2011), statin users had significantly higher odds of developing diabetes and diabetic complications that persisted throughout follow-up (odds ratio [OR] 1.93, 95 % confidence interval [CI] 1.55-2.41 and OR 2.15, 95 % CI 1.20-3.86, respectively). Short-term statin use was not associated with decreased odds of major acute cardiovascular events (OR 1.17, 95 % CI 0.72-1.92). There were no differences in risks of kidney diseases, musculoskeletal diseases, or malignancy. Short-term statin use for primary prevention in this healthy cohort was associated with an increased risk of long-term diabetes and diabetic complications without cardiovascular benefits. Further study using pragmatic studies and prospective observational studies appropriately equipped to eliminate unidentified confounders are urgently needed. |
X Demographics
The data shown below were collected from the profiles of 61 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 13% |
| Australia | 5 | 8% |
| South Africa | 4 | 7% |
| Japan | 3 | 5% |
| Spain | 3 | 5% |
| Netherlands | 2 | 3% |
| Canada | 2 | 3% |
| United Kingdom | 1 | 2% |
| Peru | 1 | 2% |
| Other | 4 | 7% |
| Unknown | 28 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 44 | 72% |
| Scientists | 9 | 15% |
| Practitioners (doctors, other healthcare professionals) | 8 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 4% |
| Netherlands | 1 | 2% |
| Unknown | 51 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 15% |
| Other | 7 | 13% |
| Student > Master | 6 | 11% |
| Student > Postgraduate | 4 | 7% |
| Researcher | 4 | 7% |
| Other | 9 | 17% |
| Unknown | 16 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 31% |
| Nursing and Health Professions | 6 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 2 | 4% |
| Psychology | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 18 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2022.
All research outputs
#1,007,935
of 25,845,749 outputs
Outputs from Drug Safety
#77
of 1,880 outputs
Outputs of similar age
#17,139
of 316,845 outputs
Outputs of similar age from Drug Safety
#2
of 24 outputs
Altmetric has tracked 25,845,749 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,880 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,845 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.